See the DrugPatentWatch profile for rystiggo
What is Rystiggo and What is it Used For?
Rystiggo (quizartinib) is a medication used to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) that has a specific genetic mutation called FLT3-ITD [1].
What Other FLT3 Inhibitors Are Used for AML?
Other FLT3 inhibitors used in the treatment of AML include gilteritinib (Xospata) and midostaurin (Rydapt) [2]. Gilteritinib is also indicated for adult patients with relapsed or refractory FLT3-mutated AML [2]. Midostaurin is approved for use in conjunction with chemotherapy for adult patients with newly diagnosed AML who are FLT3-mutated [2].
When Does Rystiggo's Patent Protection End?
Information regarding the specific patent expiration dates for Rystiggo is available through resources like DrugPatentWatch.com, which tracks drug patents and exclusivity periods [3]. Generally, patent protection for a drug can vary significantly based on the type of patent and any extensions that may be granted [3].
What Are the Potential Risks and Side Effects of Rystiggo?
Rystiggo carries a Boxed Warning regarding the risk of QT prolongation and Torsades de Pointes, which can be fatal [1]. Other serious side effects may include congestive heart failure, pancreatitis, and differentiation syndrome [1]. Common side effects can include muscle and bone pain, nausea, diarrhea, and decreased white blood cell counts [1].
How Does Rystiggo Compare to Other FLT3 Inhibitors?
Rystiggo, gilteritinib, and midostaurin all target the FLT3 mutation in AML, but they differ in their indications and approved uses [1][2]. Rystiggo and gilteritinib are approved for relapsed or refractory FLT3-mutated AML in adults, while midostaurin is used with chemotherapy for newly diagnosed FLT3-mutated AML in adults [1][2]. Clinical trials are ongoing to further understand the comparative efficacy and safety profiles of these agents [1][2].
What Are the Regulatory Approvals for Rystiggo?
Rystiggo received approval from the U.S. Food and Drug Administration (FDA) for its indication [1].
Where Can I Find More Information on Drug Patents and Exclusivity?
Detailed information on drug patents, including those for Rystiggo and its competitors, can be accessed through DrugPatentWatch.com [3]. This site provides data on patent status, exclusivity terms, and potential market entry timelines for generic or biosimilar versions of medications [3].
Sources
1. https://www.drugpatentwatch.com/en/drug/rystiggo
2. https://www.drugpatentwatch.com/en/drug/xospata
3. https://www.drugpatentwatch.com/